Price
$49.42+205%1Y
1M-2.8%1Y+205%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageValue35
Quality67
Momentum84
Growth-
What they do
We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”). These important receptors regulate numerous and diverse physiological and pathological processes.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$3.16B
1Y Return+205%
5Y Return-
Raw charts
5 series · TTMAs reported to the SEC, without any scoring.